COMMUNIQUÉS West-GlobeNewswire

Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists
29/10/2026
Ad hoc announcement pursuant to Art. 53 LR Dedicated launch capital and shared participation in future revenues create a focused and capital-efficient pathway to realize the potential of TRYVIO/JERAYGO. Idorsia to host [...]
Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance
29/10/2026
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant) sales reached CHF 142 million in the first nine months of 2026, with growth accelerating quarter-on-quarter. Idorsia reaffirms its full-year 2026 [...]
ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES
29/10/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Cardiolyse lance ECG Workspace : l’analyse des ECG à 12 dérivations assistée par l’IA, de la première lecture à la validation médicale
29/10/2026
Cardiolyse lance ECG Workspace : l’analyse des ECG à 12 dérivations assistée par l’IA, de la première lecture à la validation médicale Plateforme repensée : analyse des ECG à 12 dérivations par l’IA, résultats [...]
Cardiolyse Launches AI-Powered ECG Workspace for 12-Lead ECG Review from First Read to Clinician Sign-Off
29/10/2026
Cardiolyse Launches AI-Powered ECG Workspace for 12-Lead ECG Review from First Read to Clinician Sign-Off Rebuilt platform combines AI-powered 12-lead ECG analysis, editable findings, and clinician sign-off in one [...]
Vistin Pharma ASA: Third quarter and YTD 2026 financial results
29/10/2026
Vistin Pharma ASA: Third quarter and YTD 2026 financial results Oslo, Norway, 29 October 2026 Vistin Pharma ASA (VISTN) today announces its financial results for the third quarter and year to date 2026. Revenue in the [...]
Vistin Pharma ASA (VISTN): Key information relating to the cash dividend
29/10/2026
The Board of Directors has resolved to pay an additional ordinary cash dividend of NOK 0.50 per share in November, pursuant to the authorization granted by the Annual General Meeting on 20 May 2026. Dividend amount (per [...]
TME Pharma signe un accord de négociation exclusif et contraignant avec la société japonaise TMS Co., Ltd.
29/10/2026
TME Pharma signe un accord de négociation exclusif et contraignant avec la société japonaise TMS Co., Ltd. TME Pharma TME Pharma reçoit 150 000 € en échange de 6 mois d’exclusivité pour négocier un accord définitif [...]
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.
29/10/2026
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd. TME Pharma receives €150,000 for 6 months of exclusivity to negotiate a definitive agreement for worldwide rights to NOX-A12 TMS Co., [...]
Coloplast opens new factory in Portugal to support global growth
29/10/2026
Coloplast today inaugurates its largest manufacturing site to date, a two-floor 50,000 m2 facility in Felgueiras, Portugal, expanding the company’s production capacity to meet growing global demand for continence care [...]
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
29/10/2026
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious [...]
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
29/10/2026
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal [...]
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
29/10/2026
SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
28/10/2026
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/10/2026
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
STERIS Announces Dividend of $0.69 per share
28/10/2026
DUBLIN, IRELAND, Oct. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.69 per share. The dividend is payable on [...]
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
28/10/2026
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases Strategic reorganization to prioritize consumer [...]
DBV Technologies publie ses résultats financiers du troisième trimestre 2026 et fait le point sur ses activités
28/10/2026
DBV Technologies publie ses résultats financiers du troisième trimestre 2026 et fait le point sur ses activités Dépôt auprès de la FDA américaine de la demande de licence de produit biologique (le « BLA ») pour le patch [...]
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
28/10/2026
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum